Policy__O development__O for__O clinical__O trials__O The__O portfolio__O of__O sustained__O research__O activity__O has__O facilitated__O the__O building__O of__O relationships__O with__O regulatory__O bodies,__O professional__O societies,__O user__O groups__O and__O industry__O (e.g.__O
European__B-ORG Medicines__I-ORG Agency,__I-ORG European__I-ORG Cystic__I-ORG Fibrosis__I-ORG Society,__I-ORG UK__I-ORG Cystic__I-ORG Fibrosis__I-ORG Advocacy__I-ORG Service,__I-ORG Corporate__I-ORG Translations__I-ORG Inc.).__I-ORG
This__O has__O led__O to__O Abbott's__O expertise__O in__O quality__O of__O life__O measurement__O being__O in__O demand.__O
Abbott__B-PER has__O been__O invited__O to__O participate__O in__O continuous__O contributions__O to__O the__O UK__B-ORG Cystic__I-ORG Fibrosis__I-ORG Trust__I-ORG (Clinical__I-ORG Trials__I-ORG Advisory__I-ORG Group)__I-ORG and__O the__O European__B-ORG Cystic__I-ORG Fibrosis__I-ORG Society__I-ORG (Scientific__I-ORG committee__O 2009-date).__O
Programmes__O of__O longitudinal__O research__O have__O subsequently__O highlighted__O the__O importance__O of__O HRQoL__B-LOC measurement__O and__O allowing__O service__O users__O a__O voice__O in__O their__O healthcare5,6,a.__O
This__O research__O has__O aided__O the__O development__O of__O European__B-MISC policy__O in__O relation__O to__O the__O use__O and__O interpretation__O of__O quality__O of__O life__O data__O in__O clinical__O trials.__O
In__O 2007,__O Abbott__B-ORG contributed__O to__O the__O European__B-ORG Cystic__I-ORG Fibrosis__I-ORG Society__I-ORG consensus__O report__O concerning__O clinical__O trials__O in__O cystic__O fibrosis.__O
Subsequently,__O as__O part__O of__O the__O European__B-ORG Framework__I-ORG 6__O programme__O (LSHM-CT-2005-018932,__O EuroCareCF),__B-ORG Abbott__I-ORG led__O the__O European__B-MISC quality__O of__O life__O group__O to__O produce__O the__O guidelines__O for__O the__O measurement__O of__O quality__O of__O life__O in__O clinical__O trials__O in__O cystic__O fibrosisb.__O
Currently,__B-PER Abbott__I-PER is__O a__O member__O of__O an__O International__O multidisciplinary__O group__O (invited__O by__O the__O US__B-ORG Cystic__I-ORG Fibrosis__I-ORG Foundation__I-ORG and__O European__B-ORG Cystic__I-ORG Fibrosis__I-ORG Society)__I-ORG to__O develop__O and__O implement__O guidelines__O for__O the__O assessment__O and__O management__O of__O anxiety__O and__O depression__O in__O cystic__O fibrosis.__O
Additionally,__B-PER Abbott__I-PER was__O invited,__O by__O the__O European__B-ORG Cystic__I-ORG Fibrosis__I-ORG Society,__I-ORG to__O join__O an__O interdisciplinary__O group__O of__O nine__O world__O experts__O on__O Cystic__B-PER Fibrosis__I-PER to__O work__O with__O the__O European__B-ORG Medicines__I-ORG Agency__I-ORG (EMA).__I-ORG
The__O EMA__O is__O the__O body__O that__O regulates__O licences__O and__O constantly__O monitors__O the__O safety__O of__O medicines__O across__O the__O European__B-ORG Union.__I-ORG
Together__O with__O European__B-MISC drug__O regulators,__O representatives__O from__O international__O pharmaceutical__O companies,__O and__O patient__O representatives,__O Abbott__B-PER discussed__O and__O compiled__O current__O scientific__O evidence__O on__O outcome__O measures__O for__O evaluating__O medicines__O targeting__O CF__B-ORG lung__O disease.__O
She__O provided__O expert__O advice__O concerning__O patient-reported__O outcome__O measures__O in__O clinical__O trials__O and__O contributed__O to__O the__O revision__O of__O the__O EMA__B-ORG guidelines__O on__O `the__O clinical__O development__O of__O medicinal__O products__O for__O the__O treatment__O of__O cystic__O fibrosis'.__O
The__O proceedings__O were__O observed__O globally__O by__O the__O US__B-ORG Food__I-ORG and__O Drugs__B-ORG Administration,__I-ORG Pharmaceuticals__I-ORG and__O Medical__B-ORG Devices__O Agency,__B-PER Japan__I-PER and__O Health__B-ORG Canada__I-ORG via__O broadcastingc.__O
This__O EMA__O policy__O development__O has__O informed__O further__O research__O given__O the__O impetus__O to__O develop__O a__O brief__O global__O instrument__O to__O measure__O patient-reported__O improvement__O and__O treatment__O burden__O in__O cystic__O fibrosis__O clinical__O trials.__O
Hence,__O impact__O is__O a__O reciprocal__O two-way__O process.__O
Commercial__O applications__O outside__O academia__O The__B-MISC LupusQoL__I-MISC has__O attracted__O global__O interest__O from__O the__O pharmaceutical__O sector.__O
Inclusion__O of__O a__O patient-reported__O quality__O of__O life__O instrument__O in__O clinical__O trials__O is__O essential__O and__O will__O enable__O a__O pharmaceutical__O company__O to__O gain__O approval__O to__O market__O a__O drug__O and__O make__O licensing__O claims__O as__O to__O the__O effectiveness__O of__O the__O drug__O from__O the__O patient__O perspective.__O
Driven__O by__O demand__O from__O pharmaceutical__O companies__O to__O translate__O the__O LupusQoL__B-ORG into__O numerous__O languages__O so__O that__O the__O instrument__O could__O be__O used__O in__O multinational__O drug__O trials,__O a__O US__B-LOC translation__O company,__O Corporate__O Translations__B-PER Incd,e,__I-PER have__O developed__O a__O new__O business__O opportunity__O by__O translating__O and__O culturally__O validating__O the__O LupusQoL.__B-ORG
This__O involves__O a__O lengthy__O and__O rigorous__O harmonisation__O process__O and__O cognitive__O debriefing__O with__O patients__O to__O assess__O the__O clarity__O and__O acceptability__O of__O each__O translation.__O
They__O report__O the__O instrument__O has__O been__O used__O successfully__O in__O 51__O countries__O in__O 77__O different__O languagesf.__O
UCLan's__O licensing__O agreement__O is__O for__O Corporate__B-ORG Translations__I-ORG Inc.__I-ORG to__O be__O the__O sole__O worldwide__O distributor__O of__O the__O LupusQoL__B-ORG and__O as__O such__O they__O have__O developed__O and__O maintain__O the__O websitee.__O
The__O LupusQoL__B-ORG is__O currently__O being__O used__O in__O several__O phase__O 111__O clinical__O trials__O (predominantly__O in__O North__B-ORG America)__I-ORG to__O evaluate__O whether__O a__O specific__O drug__O can__O improve__O a__O patient's__O quality__O of__O lifeg.__O
If__O the__O products__O are__O shown__O to__O be__O effective__O the__O pharmaceutical__O company__O will__O be__O able__O to__O generate__O new__O and__O increased__O revenue__O streams__O (and__O patients__O will__O benefit__O from__O a__O drug__O that__O can__O improve__O their__O quality__O of__O life).__O
Commercial__O exploitation__O of__O the__O LupusQoL__B-ORG by__O the__O University__B-ORG Through__I-ORG UCLan's__I-ORG Innovation__I-ORG and__I-ORG Enterprise__I-ORG Unit__I-ORG and__O Strategic__B-ORG Development__I-ORG Services__I-ORG a__O new__O business__O model__O was__O identified__O and__O negotiated__O with__O partners__O (East__B-ORG Lancashire__I-ORG NHS__O Trust,__O Corporate__O Translations__B-PER Inc.)__I-PER to__O allow__O the__O sharing__O of__O Intellectual__B-ORG Property__I-ORG incomeh.__O
The__O LupusQoL__B-MISC is__O free__O to__O non-commercially__O funded__O research__O projects__O and__O for__O use__O in__O clinical__O practice,__O but__O there__O is__O a__O charge__O of__O &#163;5.00__O per__O patient__O entered__O into__O a__O commercially__O funded__O research__O study.__O
The__O licence__O income__O received__O from__O pharmaceutical__O companies__O is__O approximately__O &#163;32K;__B-ORG from__O the__O administration__O of__O approximately__O 6400__O LupusQol__B-MISC questionnaires__O in__O various__O international__O clinical__O trials.__O
Education__O and__O Capacity__B-PER building__O The__O research__O programmes__O have__O contributed__O to__O individual__O career__O development__O and__O the__O delivery__O of__O highly__O skilled__O people__O to__O the__O NHS__B-ORG and__O society.__O
Dr__O Gee__O (PhD__O student__O and__O Research__O Fellow__B-MISC involved__O in__O the__O CFQoL)__B-MISC operates__O a__O clinical__O psychology__O consultancy__O service__O and__O Dr.__O McElhone__B-PER (PhD__O student__O and__O Research__O Associate__B-MISC involved__O in__O the__O LupusQoL)__B-ORG is__O employed__O as__O a__O Specialist__B-ORG Lupus__I-ORG Research__I-ORG Nurse__I-ORG (East__I-ORG Lancashire__I-ORG NHS__O Trust)__O and__O Senior__O Research__O Fellow__I-LOC (University__I-LOC of__I-LOC Manchester).__I-LOC
They__O have__O acquired__O specialist__O knowledge__O in__O quality__O of__O life__O measurement__O and__O patient-reported__O outcomesi.__O
